PHAT
Phathom Pharmaceuticals Inc
NASDAQ: PHAT · HEALTHCARE · BIOTECHNOLOGY
$11.20
-4.92% today
Updated 2026-04-30
Market cap
$935.69M
P/E ratio
—
P/S ratio
5.34x
EPS (TTM)
$-3.03
Dividend yield
—
52W range
$2 – $18
Volume
1.2M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B6.5
Quality
B2.0
Profitability
F4.0
Valuation
C4/9
Piotroski F-Score
Moderate
-4.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$23.70
+111.61%
12-Month target
—
—
Intrinsic (DCF)
$9.46
Margin of safety
-29.28%
2 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 94.10% QoQ
+ Debt/equity -0.01x — low leverage
Risks
- Altman Z -4.68 — distress zone
- Thin margins at -126.40%
- Negative free cash flow $-5.12M
- 29.28% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $682000.00 | $55.25M | $175.11M | $175.11M |
| Net income | $-197.72M | $-201.59M | $-334.33M | $-221.25M | $-21.15M |
| EPS | — | — | — | — | $-3.03 |
| Free cash flow | $-147.57M | $-139.21M | $-266.90M | $-167.00M | $-5.12M |
| Profit margin | — | -29,558.94% | -605.09% | -126.35% | -126.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-10 | PARIKH, ASIT | Sale | 40,000 | — |
| 2026-02-27 | BREEDLOVE, ROBERT CHARLES | Buy | 13,000 | — |
| 2026-02-27 | BREEDLOVE, ROBERT CHARLES | Buy | 2,790 | — |
Peer comparison
Smart narrative
Phathom Pharmaceuticals Inc trades at $11.20. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -4.68, it sits in the distress. TTM revenue stands at $175.11M. with profit margins at -126.40%. Our DCF model estimates intrinsic value at $9.46.
Frequently asked questions
What is Phathom Pharmaceuticals Inc's stock price?
Phathom Pharmaceuticals Inc (PHAT) trades at $11.20.
Is Phathom Pharmaceuticals Inc overvalued?
Smart Value Score 31/100 (Grade F, Strong Sell). DCF value $9.46.
What is the price target of Phathom Pharmaceuticals Inc (PHAT)?
The analyst target price is $23.70, representing +111.6% upside from the current price of $11.20.
What is the intrinsic value of Phathom Pharmaceuticals Inc (PHAT)?
Based on our DCF model, intrinsic value is $9.46, a -29.3% margin of safety versus $11.20.
What is Phathom Pharmaceuticals Inc's revenue?
TTM revenue is $175.11M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-4.68 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.34x
ROE-3,489.00%
Beta0.61
50D MA$11.55
200D MA$12.53
Shares out0.08B
Float0.06B
Short ratio—
Avg volume1.2M
Performance
1 week-3.13%
1 month+6.03%
3 months-12.93%
YTD-28.99%
1 year—
3 years—
5 years—